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In this paper, we aim to underscore the need for a more nuanced understanding of vaccine non-adopters. As the
availability of vaccines does not translate into their de facto adoption—a phenomenon that may be more pro-
nounced amid “Operation Warp Speed”—it is important for public health professionals to thoroughly understand
their “customers” (i.e., end users of COVID-19 vaccines) to ensure satisfactory vaccination rates and to safeguard
society at large.A cure for COVID-19 is urgently needed. As COVID-19 outbreaks of
various sizes and the public outcry over social and economic freedom
have become the “new normal,” it is clear that physical contact–limiting
mechanisms such as lockdowns, self-isolation, and social distancing are
not sustainable long-term countermeasures against the spread of the
SARS-CoV-2 virus. It has become even clearer that non-pharmaceutical
interventions like social distancing are contingency plans; a cure for
the ever-spreading COVID-19 pandemic is expected elsewhere, most
probably in pharmaceutical solutions like COVID-19 vaccines. High
hopes are being placed on COVID-19 vaccines with the potential to curb
the spread of the novel coronavirus and, in turn, prevent societies across
the world from facing ongoing COVID-19 incidence and deaths. The plan
is simple: develop a vaccine and possibly save the world. With a pro-
nounced need for vaccines to halt the spread of COVID-19, talents
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is an open access article under tand international are bound by the same shared, determined, and fervent
desire to see the world vaccinated and return to “normal.”
Time is of the essence. Although the name “Operation Warp Speed”
refers specifically to America’s COVID-19 vaccine programs, speed has
been the focus of most (Mullard, 2020), if not all, such programs since
their inception in a race for the first approved COVID-19 vaccine. Yet in
themidst of a global health crisis, few seem to have considered COVID-19
vaccines, which are essentially consumer health products (Su et al.,
2019), in the context of the classic supply-demand economic model.
Much of the world has been concentrating on developing a vaccine,
representing the supply side of the equation. Meanwhile, not enough
questions are being asked from the demand side: who are the potential
consumers of COVID-19 vaccines? Though many vaccine programs,
whether initiated by non-profit or for-profit pharmaceutical companies,
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tential vaccines; they are not the same as end users or fundamental
consumers. In other words, although governmental demand for
COVID-19 vaccines has been most noticeable, it is individual citizens
who will be receiving these vaccines (i.e., end users). This understanding
has many implications, one of which centres on the need for a common
advertising or marketing practice—consumer analysis.
As the literature indicates, when it comes to end users of consumer
health technologies such as vaccines, their attitudes, knowledge, and in-
tentions to adopt a COVID-19 vaccine vary greatly (World Health Orga-
nization, 2014). A joint study conducted by the Associated Press and the
University of Chicago (AP-NORC) in May 2020 showed that COVID-19
vaccine availability would not translate into vaccine adoption for 51% of
Americans surveyed (The Associated Press-, 2020). Among these vaccine
non-adopters, 31% were hesitant about adopting a COVID-19 vaccine,
whereas 1 in 5 said they would refuse the vaccine outright (The Associated
Press-, 2020). These findings resonate with the results of an early study
conducted by a group of French scientists in March 2020, who found that
among a representative sample of the French population, 26% indicated
theywould refuse a COVID-19 vaccine once it becomes available (roup and
A future v, 2020). Furthermore, despite being particularly vulnerable to
COVID-19, non-adoption rates among people of low socioeconomic status
are even more alarming: approximately 37% stated they would refuse a
COVID-19 vaccine regardless of availability (roup and A future v, 2020). As
disturbing as they may be, these findings are hardly surprising (The Lancet
and Looking beyon, 2018). Research suggests that across infectious disease
contexts and vaccine types, vaccine non-adopters (often characterised as
expressing “vaccine hesitancy”) are prevalent (World Health Organization,
2014; The Lancet and Looking beyon, 2018; Larson et al., 2007).
Vaccine hesitancy poses a substantial threat to global health and is a
top 10 priority of the World Health Organization (WHO) (World Health
Organization, 2019a). Per the WHO, this phenomenon refers to “delay in
acceptance or refusal of vaccines despite availability of vaccination ser-
vices” (World Health Organization, 2015). Within the vaccine-related
literature, vaccine hesitancy is among the limited terms available that
centres on the demand rather than supply side of vaccine adoption. In
theory, the term “vaccine hesitancy” should capture only one aspect (i.e.,
reluctance) of vaccine consumers’ nuanced rationale for being vaccine
non-adopters. The crux of this issue is that “vaccine hesitancy” in fact
covers myriad distinctive reasons for vaccine non-adoption, ranging from
delay to indecision to reluctance to refusal. In other words, the term can
be used to represent a considerable proportion of vaccine non-adopters
without paying mind to these potential consumers’ distinct traits.
Therefore, the effectiveness of this definition is questionable in terms of
helping health experts better understand vaccine non-adopters’ unique
concerns about COVID-19 vaccines to address these anxieties
accordingly.
A more accurate term to refer to people who do not adopt vaccines is
“vaccine non-adopters.” Vaccine non-adopters are not one group of in-
dividuals but rather encompass many groups who possess distinct rea-
sons for vaccine non-adoption (World Health Organization, 2014). Some
vaccine non-adopters may be highly informed about vaccine efficacy and
safety, such as the efficacy of established vaccines like the flu vaccine,
and decide not to get vaccinated (Su et al., 2019). Other vaccine
non-adopters might choose not to get vaccinated because they do not
realise they must receive the vaccine to be protected from contracting
SARS-CoV-2 (roup and A future v, 2020). It is important to note that some
non-adoption decisions made by vaccine non-adopters could be based on
justified considerations (The Associated Press-, 2020), such as in-
dividuals who are allergic to egg proteins (Centers for Disease Contr,
2020). Take influenza vaccines for instance. Though some influenza
vaccines do not contain egg proteins and the Centres for Disease Control
and Prevention in the United States, for instance, no longer recommends
that people with egg allergies need to be observed for an allergic reaction
for 30 min, people who are allergic to egg proteins still need to be
vaccinated in an inpatient or outpatient medical setting (Centers for2
Disease Contr, 2020). A recent study further shows that the risk of
anaphylaxis, a severe case of vaccine hypersensitivity to allergens
ranging from egg proteins, adjuvants, preservatives, to extrinsic sub-
stances, after all vaccines is estimated to be 1.31 per million vaccine shots
(McNeil and DeStefano, 2018). While anaphylaxis cases might be
alarming from the vaccine hesitants’ perspective (McNeil and DeStefano,
2018), it is important to note that vaccines prevent approximately 2–3
million deaths every year (World Health Organization, 2019b). It is ex-
pected that COVID-19 vaccines will save a markedly greater number of
lives amid and beyond the pandemic (Yamey et al., 2020; Lurie et al.,
2020; Thanh Le et al., 2020; Graham, 2020).
Overall, it is imperative for health experts to understand that vaccine
hesitants’ cost-analysis of vaccination adoption may be drastically
different, and perhaps most importantly, may not be accurately grounded
in evidence (The Associated Press-, 2020; roup and A future v, 2020),
where even though a vaccine could save lives, livelihoods, and GDPs
(Yamey et al., 2020; Lurie et al., 2020; Thanh Le et al., 2020; Graham,
2020), an extremely low probability of vaccine-related adverse effect
may hinder their adoption behaviours (Opri et al., 2018). For people who
have egg allergies or those who perceive they may have a hypersensitive
reactions to vaccines without any clinical foundations (Opri et al., 2018),
regardless of whether a COVID-19 vaccine contains egg proteins, how
soon it becomes available, or how safe and effective it may be, they may
still be reluctant to adopt the vaccine because the perceived personal
health-related risks (i.e., an allergic reaction) outweigh the proposed
potential benefits (i.e., protection from the virus). Thus, it is important
for health experts to communicate safety measures in an informative as
well as persuasive manner (Noar et al., 2009), in order to effectively clear
these vaccine hesitants’ unjustified doubts. This is particularly relevant,
as based on available evidence (Lurie et al., 2020; Thanh Le et al., 2020;
Graham, 2020), the majority of COVID-19 vaccines may not contain egg
proteins in the first place—it is of paramount importance for health ex-
perts to deliver their evidence-based educational messages to vaccine
hesitants before anti-vaxxers’ COVID-19 misinformation or disinforma-
tion does (see Graph 1).
Other potential vaccine consumers decide not to receive vaccines for
non-scientific reasons. This group includes vaccine conspiracy theorists
(World Health Organization, 2014), whose beliefs may be instigated by
deliberate misinformation or disinformation campaigns or by the current
COVID-19 infodemic. Their conviction can further fuel unfounded, toxic
narratives surrounding COVID-19 and associated vaccines in the absence
of timely intervention. For health experts to dispel these vaccine con-
spirators’ groundless beliefs and mitigate the adverse effects of the
COVID-19 infodemic on COVID-19 vaccine adoption, experts must first
understand who these people are. More specifically, simply labelling
these individuals “vaccine non-adopters” or “hesitants” may be insuffi-
cient in providing health experts an exact, actionable understanding of
vaccine non-adopters for subsequent campaign intervention design and
development.
Rather than using the terms “vaccine non-adopters” and “vaccine
hesitants” interchangeably, health experts can consider adopting a more
precise classification of vaccine non-adopters, such as “vaccine conspir-
ators” (people who possess too much misinformation to adopt the vac-
cine), “vaccine uninformed” (people who possess insufficient
information to adopt the vaccine), and “vaccine hesitants” (people who
are considering adopting the vaccine but lack the right conditions or
context to do so) (see Fig. 1). Instead of presenting a definitive, author-
itative classification of vaccine non-adopters, this categorisation is
intended to serve as inspiration for health experts and communication
professionals. Educating three groups of vaccine non-adopters with
unique traits, rather than a single large group of vaccine non-adopters
with overlapping features, may be more cost-effective in terms of
educational materials design, communication between interventionists
and their audiences, and evaluation of intervention outcomes.
Ultimately, for health experts or communication professionals to
develop effective communication guidelines and campaign interventions
Fig. 1. A schematic representation of vaccine adopters and non-adopters.
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grained understanding of their target audiences or customers. After all,
the term “vaccine non-adopters” encompasses a large group of people
from diverse backgrounds (Larson et al., 2007), including well-educated
individuals without vaccine-related allergies who may still refuse to
adopt a COVID-19 vaccine. To ensure that meaningful population-level
SARS-CoV-2 immunity can be achieved with the help of safe and effec-
tive COVID-19 vaccines, policymakers, health experts, and health3
communication professionals should, first and foremost, understand the
many characteristics of vaccine non-adopters and develop tailored
communication strategies and campaign deliverables. Considering the
potentially grave health and financial consequences of an unvaccinated
majority once COVID-19 vaccines become available, a race for a better
understanding of the characteristics of COVID-19 vaccine non-adopters is
needed—perhaps as urgently, if not more so, as the race for effective
vaccines.Declaration of competing interest
None.
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